Abstract | INTRODUCTION: Anti-spike monoclonal antibodies were highly effective for prophylaxis and early treatment of mild-to-moderate COVID-19 in high-risk populations. AREAS COVERED: EXPERT OPINION: Anti-spike monoclonal antibodies for treatment and prevention of COVID-19 resulted in therapeutic successes that resulted in reduced morbidity and improved survival among the high-risk populations. Lessons learned from their clinical use should guide the future development of durable antibody-based therapies. A strategy that will preserve their therapeutic lifespan is needed.
|
Authors | Raymund R Razonable |
Journal | Expert opinion on biological therapy
(Expert Opin Biol Ther)
2023 Jul-Dec
Vol. 23
Issue 7
Pg. 619-631
ISSN: 1744-7682 [Electronic] England |
PMID | 37318043
(Publication Type: Journal Article, Review, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Neutralizing
|
Topics |
- Humans
- COVID-19
- SARS-CoV-2
- Antibodies, Monoclonal
(therapeutic use)
- Antibodies, Neutralizing
(therapeutic use)
- Mutation
- Post-Exposure Prophylaxis
|